Converting rabbit hybridoma into recombinant antibodies with effective transient production in an optimized human expression system

Mouse monoclonal antibodies are standard in research and diagnostic. Among all advantages of mouse monoclonal antibodies there is a lack of affinity, sensitivity and specificity especially for small epitopes and antigens that are non-immunogenic to rodents. This suggests that a huge number of diseases are under-diagnosed because of non-availability of high-quality antibodies. Rabbit monoclonal antibodies (Rab-mabs) show 10 to 100 times higher affinities than mouse monoclonal antibodies and impress by improved specificity which is extremely important in all fields of clinical and non-clinical diagnostic. However, all advantages of Rab-mabs are eliminated by the low productivity of monoclonal rabbit hybridoma. To meet the needs of IVD manufacturers InVivo implemented a rapid Rab-mab production system by transient gene expression to generate mg to g scales of highly affine, sensitive and specific IgGs within weeks.

Successful conversion of Rab-mabs into recombinant rabbit antibodies requires a combination of different scientific techniques. Firstly needed is the preparation of cDNA and sequencing of the antibody variable regions out of the rabbit hybridoma cell line. Second, synthesized full length rabbit antibody cDNA are cloned into mammalian expression vectors. Third, recombinant rabbit antibody is produced in mammalian cells preserving high productivity at good viability and suitable cell density. InVivo has implemented a novel technology for efficient transient transfection and expression in HEK cells, being especially designed for high-yielding recombinant antibody production. In brief, we developed a low cytotoxicity transfection reagent and a culture medium that can be used for transfection and production. For the establishment of an optimized host cell line for transient gene expression processes we utilized directed evolution. This completed the production platform for high throughput approaches and large scale transfection for the production of gram quantities IgG within days.

Dr. Tim Welsink presented workflow, optimization of expression and case study data on producing recombinant Rab-mabs at the HAH conference in November 2016. Click here for the final presentation as pdf

For more information about transient transfection and how to achieve the best results visit our website

Development of high producing cell lines for recombinant protein production

As part of an ILB and the state Brandenburg innovation project, InVivo works on the development of a new reporter system and optimized expression vectors for generating high producing CHO and HEK cell lines. One goal of this new method is to shorten the timeline from order entry to completion and to increase the titer of recombinant protein expression significantly. For reduction of lead time, InVivo is working on a new selection method using a cell sorter combined with reporter gene systems, making the limited-dilution approach redundant. To combine the reporter system with the realization of high expression rates, InVivo develops a new reporter and expression vector system.

Acquisition of InVivo by BRUKER

InVivo starts this year with big news!

We are pleased to announce today that BRUKER has acquired InVivo BioTech Services to expand their Molecular Biology, Microbiology and Pathology Consumables and Assay Business. As a part of BRUKER Daltonics, InVivo will continue to serve you with their well-known outstanding level of quality and service. InVivo will operate under its existing name and management team, and is looking forward to expanding its business with interesting projects.






Dr. Wolfgang Weglöhner and Mr. Siegmund Karasch, the founders and Managing Directors of InVivo BioTech, commented: “We are very pleased by the expanded opportunities for our business using the global commercial infrastructure of Bruker, particularly for microbiology and pathology.  With our molecular biology core products and CMO services, we anticipate significant growth and expansion opportunities.”

InVivo welcomes Dr. Nils Morgenthaler. He will complete the Managing Directors team of InVivo BioTech.

Click here for the official press release.